-------- -------- ------- -------- ------- --------
U.S. $574,167 $533,025 7.7 % $104,384 A $80,623 A 29.5 %
International 263,852 113,615 132.2 % 22,127 B 10,831 B 104.3 %
-------- -------- -------- -------
Total
reportable
segments $838,019 $646,640 29.6 % 126,511 91,454 38.3 %
======== ========
Corporate
functions (19,884)C (12,402)C 60.3 %
-------- -------
Income from
operations 106,627 79,052 34.9 %
Other, net (28,537)D (3,960) nm
-------- -------
Income before
income taxes $78,090 $75,092 4.0 %
======== =======
Included in the reported Income before
income taxes above, are the following charges:
A -- U.S.
Mayne Pharma acquisition related:
Acquired in-process research and
development $ - $ -
Inventory step-up charge - -
Integration and other acquisition-related
charges 1,285 -
Intangible assets amortization 3,270 -
Charges related to manufacturing
optimization initiatives 4,804 9,749
Non-recurring transition charges as a
result of the spin-off, integration and
other acquisition-related charges 454 3,605
Reduction of obligation related to the
2005 sale of the Salt Lake City, UT
'/>"/>
| SOURCE Hospira, Inc. Copyright©2007 PR Newswire. All rights reserved |